A variable fraction of anaplastic large-cell lymphomas (ALCLs) exhibits a t(2;5)(p23;q35) translocation that results in expression of the chimeric hyperphosphorylated protein NPM-ALK (p80). Tumor cells expressing NPM-ALK exhibit markedly enhanced proliferative activity, but comparative cellular kinetic studies on ALK+ (ALK lymphomas) and ALK-lymphomas are lacking. The present study showed that ALK+ lymphomas, detected with the monoclonal antibody ALKc (n = 17), had significantly higher average values for the proliferation-associated parameters mitotic index, ana/telophase index, growth index (x x mitotic index - apoptotic index, assuming x = 3), percentages of Ki-67+ cells and fraction of cells expressing cyclin A or B or the cell cycle-regulatory protein p34(cdc2) than did ALK- ALCLs (n = 15). Whether this intense proliferative activity contributes to the good response to chemotherapy and favorable outcome of ALK- ALCLs remains to be assessed in a larger series of patients. Our findings support the notion that ALK+ and ALK- ALCLs are 2 distinct disease entities.
Leoncini, L., Lazzi, S., Scano, D., Mura, A., Onda, A., Massarelli, G., et al. (2000). Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity. INTERNATIONAL JOURNAL OF CANCER, 86(6), 777-781 [10.1002/(SICI)1097-0215(20000615)86:6<777::AID-IJC4>3.0.CO;2-D].
Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity
LEONCINI, LORENZO;LAZZI, STEFANO;TOSI, PIERO;BARBINI, PAOLO;CEVENINI, GABRIELE;Massai, M. R.;GIORDANO, ANTONIO;
2000-01-01
Abstract
A variable fraction of anaplastic large-cell lymphomas (ALCLs) exhibits a t(2;5)(p23;q35) translocation that results in expression of the chimeric hyperphosphorylated protein NPM-ALK (p80). Tumor cells expressing NPM-ALK exhibit markedly enhanced proliferative activity, but comparative cellular kinetic studies on ALK+ (ALK lymphomas) and ALK-lymphomas are lacking. The present study showed that ALK+ lymphomas, detected with the monoclonal antibody ALKc (n = 17), had significantly higher average values for the proliferation-associated parameters mitotic index, ana/telophase index, growth index (x x mitotic index - apoptotic index, assuming x = 3), percentages of Ki-67+ cells and fraction of cells expressing cyclin A or B or the cell cycle-regulatory protein p34(cdc2) than did ALK- ALCLs (n = 15). Whether this intense proliferative activity contributes to the good response to chemotherapy and favorable outcome of ALK- ALCLs remains to be assessed in a larger series of patients. Our findings support the notion that ALK+ and ALK- ALCLs are 2 distinct disease entities.File | Dimensione | Formato | |
---|---|---|---|
Expression of the ALK protein by anaplastic large‐cell lymphomas correlates with high proliferative activity.pdf
accesso aperto
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
465.22 kB
Formato
Adobe PDF
|
465.22 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/19047